Harprit Singh: Future – Ready Hospitals Will Have Apheresis Hubs, Not Just Dialysis Units
Harprit Singh, Associate Director at Transfusion Technologies, Therapies, Solutions and Consultant in Transfusion Medicine at Alchemist Hospital, shared a post on LinkedIn:
“Future – Ready Hospitals Will Have Apheresis Hubs – Not Just Dialysis Units
Most hospitals don’t have an apheresis problem.
They have a utilization problem.
In multiple institutions I’ve worked with, the pattern is consistent:
- Apheresis machines exist.
- Clinical expertise exists.
- But activation pathways don’t.
The result?
- Delayed therapeutic plasma exchange (TPE)
- Underutilized apheresis services
- Missed integration with solid organ and bone marrow transplant (BMT) and oncology
- Higher ICU burden and avoidable costs
This is where strategy changes everything.
Hospitals that build Clinical Apheresis Hubs – not fragmented services – unlock the following:
- Faster intervention in critical care
- Seamless transplant and cellular therapy workflows
- Reduced ICU dependency
High-value, predictable clinical revenue
Because an Apheresis Hub is not equipment.
It is a clinical plus operational plus financial system.
Protocols define speed
Ownership defines utilisation.
The question is no longer:
‘Do we have apheresis?’
It is:
‘Is it integrated into how we deliver care?’
For COs and administrators, this is where transfusion medicine becomes strategy – not support.
A practical starting point:
Map 3 things
Who triggers apheresis?
How fast can it be activated?
How often is iused?
An open question:
What is the single biggest barrier to apheresis utilisation in your institution today?”
Stay updated with Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow